928 related articles for article (PubMed ID: 34083527)
1. Drug repurposing screens identify chemical entities for the development of COVID-19 interventions.
Bakowski MA; Beutler N; Wolff KC; Kirkpatrick MG; Chen E; Nguyen TH; Riva L; Shaabani N; Parren M; Ricketts J; Gupta AK; Pan K; Kuo P; Fuller M; Garcia E; Teijaro JR; Yang L; Sahoo D; Chi V; Huang E; Vargas N; Roberts AJ; Das S; Ghosh P; Woods AK; Joseph SB; Hull MV; Schultz PG; Burton DR; Chatterjee AK; McNamara CW; Rogers TF
Nat Commun; 2021 Jun; 12(1):3309. PubMed ID: 34083527
[TBL] [Abstract][Full Text] [Related]
2. Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19.
Mirabelli C; Wotring JW; Zhang CJ; McCarty SM; Fursmidt R; Pretto CD; Qiao Y; Zhang Y; Frum T; Kadambi NS; Amin AT; O'Meara TR; Spence JR; Huang J; Alysandratos KD; Kotton DN; Handelman SK; Wobus CE; Weatherwax KJ; Mashour GA; O'Meara MJ; Chinnaiyan AM; Sexton JZ
Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34413211
[TBL] [Abstract][Full Text] [Related]
3. Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model.
Rosenke K; Hansen F; Schwarz B; Feldmann F; Haddock E; Rosenke R; Barbian K; Meade-White K; Okumura A; Leventhal S; Hawman DW; Ricotta E; Bosio CM; Martens C; Saturday G; Feldmann H; Jarvis MA
Nat Commun; 2021 Apr; 12(1):2295. PubMed ID: 33863887
[TBL] [Abstract][Full Text] [Related]
4. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D
Cells; 2021 Dec; 11(1):. PubMed ID: 35011614
[TBL] [Abstract][Full Text] [Related]
5. Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2.
Xiao X; Wang C; Chang D; Wang Y; Dong X; Jiao T; Zhao Z; Ren L; Dela Cruz CS; Sharma L; Lei X; Wang J
Front Immunol; 2020; 11():586572. PubMed ID: 33324406
[TBL] [Abstract][Full Text] [Related]
6. High-throughput screening of the ReFRAME, Pandemic Box, and COVID Box drug repurposing libraries against SARS-CoV-2 nsp15 endoribonuclease to identify small-molecule inhibitors of viral activity.
Choi R; Zhou M; Shek R; Wilson JW; Tillery L; Craig JK; Salukhe IA; Hickson SE; Kumar N; James RM; Buchko GW; Wu R; Huff S; Nguyen TT; Hurst BL; Cherry S; Barrett LK; Hyde JL; Van Voorhis WC
PLoS One; 2021; 16(4):e0250019. PubMed ID: 33886614
[TBL] [Abstract][Full Text] [Related]
7. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
8. Drugs, Metabolites, and Lung Accumulating Small Lysosomotropic Molecules: Multiple Targeting Impedes SARS-CoV-2 Infection and Progress to COVID-19.
Blaess M; Kaiser L; Sommerfeld O; Csuk R; Deigner HP
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670304
[TBL] [Abstract][Full Text] [Related]
9. Suite of TMPRSS2 Assays for Screening Drug Repurposing Candidates as Potential Treatments of COVID-19.
Shrimp JH; Janiszewski J; Chen CZ; Xu M; Wilson KM; Kales SC; Sanderson PE; Shinn P; Schneider R; Itkin Z; Guo H; Shen M; Klumpp-Thomas C; Michael SG; Zheng W; Simeonov A; Hall MD
ACS Infect Dis; 2022 Jun; 8(6):1191-1203. PubMed ID: 35648838
[TBL] [Abstract][Full Text] [Related]
10. Biological activity-based modeling identifies antiviral leads against SARS-CoV-2.
Huang R; Xu M; Zhu H; Chen CZ; Zhu W; Lee EM; He S; Zhang L; Zhao J; Shamim K; Bougie D; Huang W; Xia M; Hall MD; Lo D; Simeonov A; Austin CP; Qiu X; Tang H; Zheng W
Nat Biotechnol; 2021 Jun; 39(6):747-753. PubMed ID: 33623157
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19.
Vicenti I; Zazzi M; Saladini F
Expert Opin Ther Pat; 2021 Apr; 31(4):325-337. PubMed ID: 33475441
[No Abstract] [Full Text] [Related]
12. AI-guided discovery of the invariant host response to viral pandemics.
Sahoo D; Katkar GD; Khandelwal S; Behroozikhah M; Claire A; Castillo V; Tindle C; Fuller M; Taheri S; Rogers TF; Beutler N; Ramirez SI; Rawlings SA; Pretorius V; Smith DM; Burton DR; Alexander LEC; Duran J; Crotty S; Dan JM; Das S; Ghosh P
EBioMedicine; 2021 Jun; 68():103390. PubMed ID: 34127431
[TBL] [Abstract][Full Text] [Related]
13. Suramin Inhibits SARS-CoV-2 Infection in Cell Culture by Interfering with Early Steps of the Replication Cycle.
Salgado-Benvindo C; Thaler M; Tas A; Ogando NS; Bredenbeek PJ; Ninaber DK; Wang Y; Hiemstra PS; Snijder EJ; van Hemert MJ
Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32513797
[TBL] [Abstract][Full Text] [Related]
14. A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval.
Ashour NA; Abo Elmaaty A; Sarhan AA; Elkaeed EB; Moussa AM; Erfan IA; Al-Karmalawy AA
Drug Des Devel Ther; 2022; 16():685-715. PubMed ID: 35321497
[TBL] [Abstract][Full Text] [Related]
15. Predicting Potential SARS-COV-2 Drugs-In Depth Drug Database Screening Using Deep Neural Network Framework SSnet, Classical Virtual Screening and Docking.
Karki N; Verma N; Trozzi F; Tao P; Kraka E; Zoltowski B
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33557253
[TBL] [Abstract][Full Text] [Related]
16. A Bioluminescent 3CL
Mathieu C; Touret F; Jacquemin C; Janin YL; Nougairède A; Brailly M; Mazelier M; Décimo D; Vasseur V; Hans A; Valle-Casuso JC; de Lamballerie X; Horvat B; André P; Si-Tahar M; Lotteau V; Vidalain PO
Viruses; 2021 Sep; 13(9):. PubMed ID: 34578395
[TBL] [Abstract][Full Text] [Related]
17. Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system.
Yuan S; Chan JFW; Chik KKH; Chan CCY; Tsang JOL; Liang R; Cao J; Tang K; Chen LL; Wen K; Cai JP; Ye ZW; Lu G; Chu H; Jin DY; Yuen KY
Pharmacol Res; 2020 Sep; 159():104960. PubMed ID: 32473310
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 replicon for high-throughput antiviral screening.
Zhang QY; Deng CL; Liu J; Li JQ; Zhang HQ; Li N; Zhang YN; Li XD; Zhang B; Xu Y; Ye HQ
J Gen Virol; 2021 May; 102(5):. PubMed ID: 33956592
[TBL] [Abstract][Full Text] [Related]
19. The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication
Shytaj IL; Fares M; Gallucci L; Lucic B; Tolba MM; Zimmermann L; Adler JM; Xing N; Bushe J; Gruber AD; Ambiel I; Taha Ayoub A; Cortese M; Neufeldt CJ; Stolp B; Sobhy MH; Fathy M; Zhao M; Laketa V; Diaz RS; Sutton RE; Chlanda P; Boulant S; Bartenschlager R; Stanifer ML; Fackler OT; Trimpert J; Savarino A; Lusic M
mBio; 2022 Apr; 13(2):e0370521. PubMed ID: 35229634
[TBL] [Abstract][Full Text] [Related]
20. Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV.
Aherfi S; Pradines B; Devaux C; Honore S; Colson P; Scola B; Raoult D
Future Microbiol; 2021 Nov; 16():1341-1370. PubMed ID: 34755538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
